Navigation Links
Rosetta Genomics Announces Exclusive Distribution Agreement With Teva Pharmaceutical Industries Ltd.
Date:1/8/2009

ivate Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including risks related to: Rosetta's approach to discover microRNA technology and to work on the application of this technology in the development of novel diagnostics and therapeutic tools, which is unproven and may never lead to commercially accepted products or services; Rosetta's ability to obtain, maintain and protect its intellectual property; Rosetta's ability to enforce its patents against infringers and to defend its patent portfolio against challenges from third parties; Rosetta's need and ability to obtain additional funding to support its business activities; Rosetta's dependence on third parties for development, manufacture, marketing, sales, and distribution of products; Rosetta's ability to successfully develop its candidate tools, products and services,; Rosetta's ability to obtain regulatory clearances or approvals that may be required for its products and services; the ability to obtain coverage and adequate payment from health insurers for the products and services comprising Rosetta's technology; competition from others using technology similar to Rosetta's and others developing products for similar uses; Rosetta's dependence on collaborators; and Rosetta's short operating history; as well as those risks more fully discussed in the "Risk Factors" section of Rosetta's Annual Report on Form 20-F for the year ended December 31, 2007 as filed with the Securities and Exchange Commission. In addition, any forward-looking statements represent Rosetta's views only as of the date of this release and should not be relied upon as representing its views as of any subsequent date. Rosetta does not assume any obligation to update any forward-looking statements unless required by law.

    Contact:
    Media& Investors
    Ron Kamienchi
'/>"/>
SOURCE Rosetta Genomics Ltd
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Rosetta Genomics Announces Annual General Meeting of Shareholders to be Held on September 24, 2007
2. NYU Medical Center Collaborates With Rosetta Genomics to Develop a microRNA-Based Diagnostic Test for Melanoma
3. Rosetta Genomics to Present at the American Association of Cancer Research (AACR) "Molecular Diagnostics in Cancer Therapeutic Development" Conference
4. Rosetta Genomics to Webcast Presentation at Maxim Group Growth Conference
5. Rosetta Genomics to Host and Webcast its R&D Day on Friday, October 26, 2007
6. Rosetta Genomics Will Host and Webcast its R&D Day on Friday, October 26, 2007
7. Rosetta Genomics Announces Initiation of In Vivo Studies Following Successful Completion of First Milestone in MicroRNA-based Therapeutic Program for Liver Cancer
8. Rosetta Genomics Selects PCR as Platform for its microRNA-based Diagnostics to be Launched in 2008, Licensed Nanogens MGB Probe Technology
9. Rosetta Genomics and Columbia University Medical Center to Develop MicroRNA-based Diagnostics for Leukemia and Non Hodgkin Lymphoma
10. Rosetta Genomics Announces Initiation of Expansion of US Operations to Facilitate Expected Product Launches in 2008
11. Henry Ford Hospital and Rosetta Genomics to Develop MicroRNA-based Diagnostics for Brain Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 15, 2014 2013 was a banner ... State Technologies®. They saw continued independent research led by ... were awarded a $1 million grant from the Susanne ... and Behavior” a peer reviewed journal, Amy Grant highlighted ...
(Date:1/14/2014)... Date: Friday, April 11, 2014 , Time: 6 p.m. – ... Warrington, Pa. , Details: The Hepatitis B Foundation, ... cure for hepatitis B and improving the quality of life ... on Friday, April 11 at Warrington Country Club in Warrington, ...
(Date:1/14/2014)... pet owners drew up their lists of New Year,s resolutions for ... of my furry companion." Nowadays there are pet salons, dog and ... take the little canine or feline darlings along wherever mommy or ... pricey toys at the pet store. But anyone who has ever ...
(Date:1/14/2014)... iLab Solutions, the leader in core facility ... of Product Strategy. In this role, Michelle will work with ... guide in the development of iLab products. Her main goal ... benefit to the scientific community by offering the most advanced, ...
Breaking Biology Technology:Dynamic Innovative Technology Showcased at Scottsdale Company’s Open House 2Dynamic Innovative Technology Showcased at Scottsdale Company’s Open House 3Hepatitis B Foundation to Host Annual Crystal Ball Gala 2New Year's Resolution: Give Pets the Gift of Top-Notch Health Care 2iLab Solutions Announces Michelle Detwiler as the New Director of Product Strategy 2
... , June 21 /PRNewswire-FirstCall/ - Aeterna Zentaris ... a late-stage drug development company specialized in oncology and ... announced registered direct offering of US$12.1 million ... purchase warrants to certain institutional investors. Net proceeds from ...
... June 21, 2010 The Pharmaceutical practice,at MarketsandMarkets is pleased to announce a new report ... , ... , , ... , , ...
... in power capacity as a result of a new finding ... for one of the battery,s electrodes produced a significant increase ... it could deliver from a given weight of material, compared ... in small portable devices, and with further research might also ...
Cached Biology Technology:Aeterna Zentaris Receives US$12 Million on Closing of Registered Direct Offering 2Aeterna Zentaris Receives US$12 Million on Closing of Registered Direct Offering 3Top 10 Drug Delivery Technologies (2010 - 2015): MarketsandMarkets 2Top 10 Drug Delivery Technologies (2010 - 2015): MarketsandMarkets 3Top 10 Drug Delivery Technologies (2010 - 2015): MarketsandMarkets 4Using carbon nanotubes in lithium batteries can dramatically improve energy capacity 2Using carbon nanotubes in lithium batteries can dramatically improve energy capacity 3
(Date:7/9/2014)... candidate developed by researchers at the NIH,s ... and its collaborators to treat sickle cell ... BioScience business. The drug candidate, Aes-103, is ... underlying molecular mechanism of sickle cell disease. ... activities required for regulatory approval and commercialization. ...
(Date:7/9/2014)... southern Europe are less fit in terms of ... European peers. Moreover, southern adolescents are more obese ... fat than those from the centre-north of Europe. ... from an ambitious study conducted by scientists from ... in collaboration with 25 other European research groups. ...
(Date:7/9/2014)... yield big savings, if they are used in ... the Brigham and Women,s Hospital and coauthors analyzed ... savingshigh-cost patients; readmissions; triage; decompensation (when a patient,s ... a disease affects multiple organ systems. They suspect ... current costs associated with all six scenarios will ...
Breaking Biology News(10 mins):First drug candidate from NIH program acquired by biopharmaceutical company 2First drug candidate from NIH program acquired by biopharmaceutical company 3First drug candidate from NIH program acquired by biopharmaceutical company 4Adolescents from southern Europe are less fit and more obese than central-northern European peers 2The impact of big data on health care: Health Affairs' July issue 2
... CITY, MO Cells trying to keep pace with constantly ... between maintaining their genomic integrity and allowing enough genetic ... study, researchers at the Stowers Institute for Medical Research ... genomes become unstable, readily acquiring or losing whole chromosomes ...
... the genetic variance of human metabolism, researchers have identified ... with levels of circulating metabolites, i.e., small molecules that ... Many of the studied metabolites are biomarkers for cardiovascular ... provide valuable insight into the biological processes leading to ...
... the researchers to see an aspect of light that humans ... sensitive to polarized light, many reef dwelling animals are but ... studies of reef communities. Thanks to generous support provided ... team of researchers from the Ecology of Vision Laboratory in ...
Cached Biology News:That which does not kill yeast makes it stronger 2That which does not kill yeast makes it stronger 3Genetic regulation of metabolomic biomarkers - paths to cardiovascular diseases and type 2 diabetes 2Capturing an octopus-eye view of the Great Barrier Reef 2
... SYBR Green II RNA gel stain ... has bright fluorescence when bound to RNA and ... use with either formaldehyde/agarose or polyacrylamide gels using ... stains 50 minigels. A 1 mL unit size ...
Sirtuin 7 (SIRT7) Rabbit anti-Human Polyclonal Antibody Immunogen: Synthetic peptide - KLH conjugated Family: Other Recommended Storage: Long term: -20C; Short term: +4C...
... RSH-4000 is the only microplate sealer with ... long walkaway times with a variety of ... Fully automated with integrated stacker and 240-plate ... EX for use in small workcells , ...
... Reagents for the differentiation of mouse embryonic ... bodies exist in the midbrain, where they ... the ventral tegmental area, and the retrorubral ... to extensive forebrain dopamine innervation ( e.g.projections ...
Biology Products: